# Aldeyra Therapeutics
 (stock symbol: ALDX) Logo in transparent PNG and SVG formats

## Aldeyra Therapeutics
 Logo large

### Aldeyra Therapeutics
 Logo large Download PNG (53 KB)

![Aldeyra Therapeutics
 Logo large Download PNG (53 KB)](/img/orig/ALDX_BIG-e850fec0.png)

### Aldeyra Therapeutics
 Logo large Download SVG (3.56 KB)

![Aldeyra Therapeutics
 Logo large Download SVG (3.56 KB)](/img/orig/ALDX_BIG-93dd118c.svg)

## Aldeyra Therapeutics
 Logo icon format

### Aldeyra Therapeutics
 Logo icon format Download PNG (44.11 KB)

![Aldeyra Therapeutics
 Logo icon format Download PNG (44.11 KB)](/img/orig/ALDX-643d9a27.png)

### Aldeyra Therapeutics
 Logo icon format Download SVG (1.11 KB)

![Aldeyra Therapeutics
 Logo icon format Download SVG (1.11 KB)](/img/orig/ALDX-2eeb0acc.svg)

## Aldeyra Therapeutics
 Logo large for dark backgrounds

### Aldeyra Therapeutics
 Logo large for dark backgrounds Download PNG (32.86 KB)

![Aldeyra Therapeutics
 Logo large for dark backgrounds Download PNG (32.86 KB)](/img/orig/ALDX_BIG.D-827f85e2.png)

### Aldeyra Therapeutics
 Logo large for dark backgrounds Download SVG (3.54 KB)

![Aldeyra Therapeutics
 Logo large for dark backgrounds Download SVG (3.54 KB)](/img/orig/ALDX_BIG.D-9e4aa6ec.svg)

## Aldeyra Therapeutics
 Logo icon format for dark backgrounds

### Aldeyra Therapeutics
 Logo icon format for dark backgrounds Download PNG (26.47 KB)

![Aldeyra Therapeutics
 Logo icon format for dark backgrounds Download PNG (26.47 KB)](/img/orig/ALDX.D-508c9ce4.png)

### Aldeyra Therapeutics
 Logo icon format for dark backgrounds Download SVG (1.09 KB)

![Aldeyra Therapeutics
 Logo icon format for dark backgrounds Download SVG (1.09 KB)](/img/orig/ALDX.D-7e58601b.svg)

## About Aldeyra Therapeutics


Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

1. Website domain: aldeyra.com
2. Employees: 15
3. Marketcap: $0.55 Billion USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
